chromatography are the simpler extraction procedure, elimination of the need for a derivitization step with silylating agents, and a 20-fold greater sensitivity. The minimum detectable concentration of 5-fluorouracil in plasma is 25 tg/L. The enhanced sensitivity enabled measurement of the concentrations of 5-fluorouracil found in plasma of patients receiving continuous intravenous infusions of the drug: such concentrations are generally unmeasurable by gas-chromatographic methods.
We compared liquidchromatographic and gas-chromatographic measurements on 36 plasma samples obtained from patients after rapid intravenous injection of 5-fluorouracil. The resulting correlation coefficient was 0.97, with a regression slope of 0.94. The liquid-chromatographic method is free of interference from other cytotoxic agents, anti-emetics, and folate derivatives that are frequently combined with 5-fluorouracil therapy.
The first reported methods for measuring the cytotoxic agent 5-fluorouracil in plasma were bioassays (1, 2) and gas chromatography (3, 4) . Recently Hillcoat et al. (5) described a gas chromatographic-mass spectrometric method, which is sensitive enough to measure the drug in plasma during slow intravenous infusion therapy. Concentrations of the drug in plasma of these patients are generally in the microgram per litre range, below the lower limit of sensitivity for conventional gas-chromatographic methods (6). "High-performance" liquid chromatography is being used increasingly formeasuring cytotoxicagents in biological fluids (7-9), and we present here a new method for its use in measuring 5-fluorouracil in plasma. It has the advantages of a simpler extraction procedure and avoids the time-consuming drying step under nitrogen and derivitization with dangerous silylating agents that is necessary in gas-chromatographic methods. The sensitivity of the proposed method is in the range reported for gas chromatography-mass spectrome-
try.
We could measure plasma 5-fluorouracil in 36 plasma samples obtained from four patients who received the drug by rapid intravenous bolus injection and compare the results with those obtained by gas-chromatographic analysis. We also 
Materials and Methods

Chemicals
Pure 5-fluorocytosine, used as the internal standard, and 5-fluorouracil were obtained from F. 
Patient Sampling Procedures
Samples were obtained from eight patients with tumors of the large bowel. Four patients were receiving 12-15 mg of 5-fluorouracil per kilogram body weight by rapid intravenous bolus injection at one-week intervals. On one of these occasions 5-mL samples of venous blood were taken 15 mm before the dose and again at intervals during 90 mm after it. Each blood sample was collected with sodium citrate as anticoagulant and the plasma was removed after centrifugation and stored at -20 #{176}C. A total of 36 post-dose samples were collected from the four patients. A further 15 plasma samples were collected from four patients receiving continuous intravenous infusion of 5-fluorouracil (20 to 30 mg kg-' per 24 h for five days); see Table 1 . All plasma samples were assayed by both chromatographic techniques.
Extraction Procedure for Liquid Chromatography and centrifugation as before, aspirate the organic solvent phase and discard it. Adjust the aqueous phase to neutral pH adding 10 L of 1 mol/L H2S04, and inject 25 ML of this mixture into the chromatograph.
Prepare standard curves by adding pure 5-fluorouracil in concentrations of 50, 100, 250, 500, 750, 1000, 2500, 5000, 10 000, 25 000, 50 000 and 100 000 g/L to pooled drug-free plasma. Then treat these samples as described above. Determine the concentrations of 5-fluorouracil from a graph relating peak height ratios of 5-fluorouracil to 5-fluorocytosine (the internal standard), and to the concentration of known standards.
Results
Elution Characteristics Figure 1 shows some representative chromatograms. They
show the sharp, distinct peaks produced by 5-fluorouracil and 5-fluorocytosine, with retention times of 5.0 and 3.8 mm, respectively.
In blank plasma ( Figure 1A) , two small components are apparent, with retention chracteristics of 3.8 and 4.6 mm. Both were clearly separate from the 5-fluorouracil peak but the former interfered with 5-fluorocytosine. This peak was consistently present in chromatograms of pooled plasma and patients' plasma; in 5-fluorouracil-fortified plasma, chromatographed without added 5-fluorocytosine, it was always less than 4% of the 5-fluorocytosine peak. It therefore did not interfere notably with calculation of 5-fluorouracil in patients' plasma samples.
Other Analytical Variables
Precision:
Within-run precision of the assay was determined by processing aliquots of pooled plasma through the procedure during a single day. The coefficients of variation (CV) were found to be 4% at 700 g/L (n = 6) and 3% at 23 mg/L (n = 6). Using different plasma samples supplemented with 50 g of 5-fluorouracil per litre, the within-run CV was 4% (n = 6). Day-to-day precision, determined during 12 weeks, is shown in Table 1 .
Analytical recovery: The analytical recovery of fluorouracil from plasma was 75%. This was calculated from the ratio of the peak height for 5-fluorouracil obtained after extraction of a known amount of the drug added to plasma to the peak height when the same amount was added to a buffer solution.
Linearity and sensitivity:
Linear calibration curvespassing through the origin were obtained by supplementing blank plasma with known amounts of 5-fluorouracil, ranging from The standard deviation in the slopes of the two curves was ±0.03 and ±0.03, respectively. The two curves were not significantly different (t = 1.87, p = >0.05).
Interference:
Other cytotoxicdrugs sometimes used clinically in combination with 5-fluorouracil did not interfere with this assay when 1 mg/L standard solutions were tested. The ymca alkaloids, doxorubicin, daunorubicin, methotrexate, leucovorin, cytosine, arabinoside, cyclophosphamide, mitomycin, mithramycin, and bleomycin were chromatographed under the conditions of the proposed assay and their elution profiles did not interfere with the assay. The anti-emetics thiethylperazine, prochlorperazine, and cyclizine also did not interfere.
Comparison with Gas-Liquid Chromatography
In patients with plasma fluorouracil concentrations exceeding 500 ,sg/L there was a close correlation between results by the two methods of measurement, with a correlation coefficient of 0.97 and a regression slope that was close to unity (see Figure 2) . Concentrations between 50 and 500 g/L were below the sensitivity of the gas-chromatographic assay and no such comparison could be made. However, the slope of the calibration curve in the tg/L range was 1.23 ± 0.03 (1 SD), which did not differ significantly from that in the mg/L range, 1.25 ± 0.03 (t = 1.47, p > 0.05).
Plasma 5-Fluorouracil
Concentrations During Continuous Infusions, as Determined by HPLC Table 2 contains our data on 5-fluorouracil concentrations in plasma sampled from patients during chronic continuous infusions of 5-fluorouracil in doses of 20 to 30 mg kg' body weight 24 h'.
Measured by the liquid-chromatographic method, they range from 50 to 700 g/L and are generally below the concentrations measurable by the gas-chromatographic method. A typical chromatogram from such a sample is shown in Figure 1D .
Discussion
The results presented indicate that the proposed liquid chromatographic method is sufficiently sensitive and precise to measure plasma 5-fluorouracil concentrations in the clinically relevant concentration range. The proposed method has the advantage over previously described gas-chromatographic procedures (3, 4) 
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twice that quoted in the manufacturer's specifications. The high sensitivity of this method is partly attributable to the high molar absorptivity (r = 7070) and the sharpness of the chromatographic elution characteristics of this compound under the conditions described.
The small endogenous component that eluted with retention chracteristics similar to those of the internal standard, 5-fluorocytosine, did not interfere with quantitation. However, there was no statistical difference in the slopes of the liquidchromatography calibration curve in the g/L range from that in the mg/L range. Evidently this method measures the same substance (5-fluorouracil) in the concentrations above and below the lower limit of sensitivity of the gas-chromatographic assay.
We could measure plasma 5-fluorouracil values in patients receiving prolonged intravenous infusion of the drug: 50 to 700 g/L, values generally below the lower limit of sensitivity for gas-chromatography. Comparable plasma concentrations were reported by Hillcoateta!.(5). The increased sensitivity of gas chromatography-mass spectrometry (5), which measures concentrations less than ,zg/L of plasma, is offset by the ease of use of the present method, which is satisfactory for all clinical purposes.
Further advantages of the method over published gaschromatographic methods are the simplicity of extraction, elimination of the drying step, and avoidance of derivatization. Sample preparation and chromatography time are short; therefore about 30 samples can be handled daily. The statistically significant correlation between assay results obtained from aliquots of the same sample measured here by both techniques indicates that the liquid-chromatographic method is a specific, sensitive, and precise alternative method for measuring plasma 5-fluorouracil clinically.
